"A number of well-respected institutions have invested in Derma Sciences now and we view this as validation of our development strategy of the past five years. We plan to use these funds to work with the FDA to advance our drug DSC127 into a Phase 3 trial we plan to commence during the first half of 2012," said Edward J. Quilty, chairman and chief executive officer of Derma Sciences. "DSC127 has shown great potential in the complete healing of diabetic foot ulcers in our recently reported Phase 2 trial, with healing rates exceeding any currently approved products and above the endpoints of the trial design. We estimate that the annual sales for a product such as DSC127 could be as much as $900 million worldwide. If approved, we believe this drug will fill an important unmet clinical need for the nearly 3 million diabetics with these ulcers globally, who without good treatment results could face consequences including amputation and death.